Apogee Therapeutics (APGE) | Stock Overview & Key Data
Apogee Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $36.42
High: $38.88
on August 22, 2025
52 Week Range
Low: $26.20
High: $63.50
on April 8, 2025
on November 11, 2024
All-Time High: $72.29 on March 11, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$2.3B
EPS
-4.14
P/E Ratio (TTM)
-11.69
Forward P/E
-10.07
P/B Ratio
3.62
PEG Ratio
-0.13
Div. Yield
N/A
ROE
-34.12%
Beta
1.442
Debt to Equity
1.75
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
0.00%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-23.21%
Return on Equity (TTM)
-34.12%
EBITDA
$-270.1M
Net Income (TTM)
$-237.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
N/A
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Apogee Therapeutics APGE | 2.28B Mid-cap | 2.63% | -3.36% | -5.18% | 14.68% | -18.83% | -20.86% | 80.26% | 80.26% |
| Vertex VRTX | 101.31B Large-cap | 0.59% | -15.96% | -8.96% | -17.97% | -2.62% | -17.90% | 40.27% | 46.36% |
| Regeneron REGN | 63.57B Large-cap | 1.56% | 5.09% | -1.23% | -17.35% | -17.58% | -50.84% | -1.12% | -2.18% |
| BridgeBio Pharma BBIO | 9.58B Mid-cap | -4.36% | 7.23% | 48.86% | 35.39% | 74.04% | 93.92% | 368.32% | 65.87% |
| Madrigal MDGL | 9.07B Mid-cap | 12.12% | 32.32% | 51.70% | 28.73% | 32.16% | 64.07% | 491.89% | 288.86% |
| Halozyme HALO | 8.38B Mid-cap | 6.76% | 24.82% | 33.62% | 22.77% | 49.59% | 14.51% | 78.26% | 152.53% |
Ownership & Short Interest
Insider Ownership
7.60%
Institutional Ownership
132.02%
Shares Short
8M
Short Ratio
7.01
Short % of Shares Outstanding
30.66%
Average 10-Day Volume
433K
Average 90-Day Volume
584K
Apogee Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Apogee Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is APGE's 52-week high and low?
- In the last 52 weeks, Apogee Therapeutics reached a high of $63.50 (on November 11, 2024) and a low of $26.20 (on April 8, 2025).
- What is the market cap and P/E ratio for APGE?
- Curious about Apogee Therapeutics's size and valuation? Its market capitalization stands at 2.28B. When it comes to valuation, the P/E ratio (trailing twelve months) is -11.69, and the forward P/E (looking ahead) is -10.07.
- Does APGE pay dividends? If so, what's the yield?
- As for dividends, Apogee Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Apogee Therapeutics's main competitors or similar companies to consider before investing?
When looking at Apogee Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX101.31B Healthcare Biotechnology -17.90% 40.27% Regeneron
REGN63.57B Healthcare Biotechnology -50.84% -1.12% BridgeBio Pharma
BBIO9.58B Healthcare Biotechnology 93.92% 368.32% Madrigal
MDGL9.07B Healthcare Biotechnology 64.07% 491.89% Halozyme
HALO8.38B Healthcare Biotechnology 14.51% 78.26% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Apogee Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Apogee Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -34.12%, the Debt to Equity ratio from the most recent quarter is 1.75, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for APGE?
- Looking at Apogee Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of APGE stock is held by insiders and institutions?
- Wondering who owns Apogee Therapeutics stock? Company insiders (like executives and directors) hold about 7.60% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 132.02%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.